This article is a balanced presentation about the risks and benefits of a weight lost drug (Xenical) that is currently marketed as the prescription medication Orlistat and is under current consideration by the FDA for over-the-counter distribution. Use of xenical along with diet and exercise can result in modest weight loss that may result in beneficial health outcomes. The common side effects (seen in ~70%) of consumers of this medication include flatulence, increased bowel movements, diarrhea and anal leakage.
Estimates cost to be $2-3 /day.
Provides at least a ball park estimate for people about the amount of weight that might be
anticipated to be lost with the use of this medication.
The story explains that about 70% of users experience gastrointestinal
complications and lists some.
While discussion of a particular study is provided, there is no information
about the nature of the study (i.e. randomized or not) and no details that would permit the reader to access the reference.
Brief mention of
medical benefits that can be gained from the amount of weight loss attained with the use of xenical (e.g. lower BP, improved
cholesterol levels, reduced risk of diabetes).
Provides quotes from drug maker, researchers, and public watchdog organization
Article presents
information on weight loss results from xenical, diet, and exercise (7% of body weight) compared with diet and exercise (4%
of body weight) over a 4 year period. The story did not mention sibutramine, another prescription weight loss drug.
Article
includes the fact that the switch in status from prescription only to OTC is under FDA consideration.
Article is about a
medication, xenical, available by prescription that is being considered for sale as an over-the-counter (OTC) drug.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like